307 related articles for article (PubMed ID: 24310792)
41. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Satoi S; Yanagimoto H; Toyokawa H; Takahashi K; Matsui Y; Kitade H; Mergental H; Tanigawa N; Takai S; Kwon AH
Pancreas; 2009 Apr; 38(3):282-8. PubMed ID: 19142173
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
43. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
46. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
47. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
[TBL] [Abstract][Full Text] [Related]
48. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
[TBL] [Abstract][Full Text] [Related]
49. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
50. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
[TBL] [Abstract][Full Text] [Related]
51. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy.
Kamachi H; Tsuruga Y; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamiyama T; Katoh N; Taketomi A
In Vivo; 2018; 32(5):1183-1191. PubMed ID: 30150442
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
[TBL] [Abstract][Full Text] [Related]
54. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Jan; 79(1):37-47. PubMed ID: 27878355
[TBL] [Abstract][Full Text] [Related]
55. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
[TBL] [Abstract][Full Text] [Related]
56. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819
[TBL] [Abstract][Full Text] [Related]
57. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
58. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
59. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.
Tsuchikawa T; Hirano S; Tanaka E; Matsumoto J; Kato K; Nakamura T; Ebihara Y; Shichinohe T
Cancer Sci; 2013 May; 104(5):531-5. PubMed ID: 23363422
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
